Nutromics wins best early-stage project award

Nutromics took home the coverted ‘Best Translational Research’ award at AusMedtech 2021’s Early-Stage Investment Forum, after winning the pitching event judged by an expert investment panel.

Nutromics’ Head of Commercial and Intellectual Property Ms Rosie Stramandinoli presented the company’s wearable Continuous Molecular Monitoring (CMM) platform which can measure a wide array of molecular targets continuously and in real time, including drugs, hormones, metabolites, and proteins. This platform technology enables clinicians to receive continuous real-time molecular data to accurately dose a patient and keep them within a narrow therapeutic range. Nutromics’ vision is to create a world with zero preventable deaths due to the lack of timely, molecular-level data.

Commenting on her win Rosie said “I was honoured to present Nutromics’ vision at the Early-Stage Investment Forum and thrilled that the technology resonated with the judges. Nutromics will be closing a funding round soon and this win, along with the one-on-one mentoring with Medtronic ANZ, will go a long way in helping us turn our vision into reality.”

Partnering with AusBiotech to deliver the Early-Stage Investment Forum, Medtronic ANZ’s Business Development & Strategy Manager Jamie Platt will mentor Nutromics for six months, includes in-depth and personalised pitch analysis, expert insight into future planning, and access to key industry contacts to help with preparation, negotiating, growth, and closure.

AusBiotech also extends its thanks to the expert panellists who generously shared their insights and experience with the 15 presenters during the Forum: Sarah Meibusch, Principal, One Ventures; Steven Suchting, Investment Director, IP Group PLC; Kathy Connell, Senior Director, New Ventures, Australia & New Zealand, Johnson & Johnson Innovation; and Jamie Platt, Business Development and Strategy Manager, Medtronic.

The successful initiative offers feedback essential for commercialising early-stage projects and technologies, and is one aspect of AusBiotech’s work in empowering start-ups and SMEs during their commercialisation journey.

Featured at the annual AusBiotech conference since 2018, this was the first time the Forum was held at AusMedtech 2021, Australia’s premier medtech event. A strong number of applications were received for the initiative, demonstrating the healthy research pipeline that Australia fosters.

The Forum featured rapid-fire rounds of quick-pitch presentations from early-stage technologies and projects from local research institutes, universities, hospitals and pre-series A companies in the areas of medical devices and diagnostics, digital health and enabling technologies.

AusMedtech 2021: Reimagine and reconnect offered a week of inclusive half-day virtual sessions that represented Australia’s medtech industry. Reconnect with a network of resilient and innovative leaders, and reimagine the future of medtech beyond our borders.

Run by industry, for industry, AusMedtech week featured a mix of cutting edge leading keynotes, expert panel discussions, and Q&A, bringing together key stakeholders of the Australian and international medical devices and diagnostics sector to help prepare the industry sector for its changing landscape.

AusMedtech 2021 was supported by the Victorian Government as the Host State Partner.

Registered delegates can rewatch content on-demand until 21 June 2021.

/Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.